Cocrystal Pharma, Inc. (COCP) Announces 26M Bought Deal Offering at $1.54/Sh

Cocrystal Pharma, Inc. (NASDAQ: COCP) today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 26,000,000 shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about May 7, 2021, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The gross proceeds to Cocrystal, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $40 million. The Company intends to use the net proceeds from this offering for the expansion of its COVID-19 and Influenza treatment development programs and general corporate purposes and working capital.

The shares of common stock are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-237738) originally filed with the Securities and Exchange Commission (the "SEC") on April 17, 2020, and declared effective by the SEC on May 13, 2020.

You May Also Be Interested In

• Vincerx Pharma (VINC) Announces Proposed Share and Warrant Offering
• IBM (IBM) to Acquire HashiCorp (HCP) for $35/sh Cash or $6.4B
• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts